ライフサイエンスコーパス: be planned

1 uate fund allocation for delivery of care to be planned.

2 hat acceptable alternative interventions can be planned.

3 mic stroke in whom endovascular thrombectomy is planned.

4 opathy can occur later, so further follow-up is planned.

5 icentre, cluster randomised controlled trial is planned.

6 A phase III study of palliative liver RT is planned.

7 ailure in men for whom radical prostatectomy is planned.

8 Radiation therapy is planned.

9 Further testing of this regimen is planned.

10 duction of diabetes if islet transplantation is planned.

11 candidate vaccine by intramuscular injection is planned.

12 antinib and erlotinib in patients with NSCLC is planned.

13 er clinical evaluation of pazopanib in NSCLC is planned.

14 yndromes for whom an early invasive strategy is planned.

15 ction or if highly immunosuppressive therapy is planned.

16 ants, especially when an NNRTI-based regimen is planned.

17 ase II study in resectable pancreatic cancer is planned.

18 rrently with routine immunization in infants is planned.

19 e is overt bleeding or an invasive procedure is planned.

20 ing CT with genomic and proteomic assessment is planned.

21 lticenter trial with patient-specific dosing is planned.

22 ia control into routine health-care delivery is planned.

23 f NSCLC patients for whom definitive therapy is planned.

24 hoid conjugate vaccine within Hyderabad city is planned.

25 platinum-sensitive recurrent ovarian cancer is planned.

26 ostate cancer and a randomised phase 3 study is planned.

27 ith multiple visualization tools for reports is planned.

28 n patients with trauma and severe hemorrhage is planned.

29 is recommended especially if ptosis surgery is planned.

30 Continuation of the presented EQA scheme is planned.

31 Burden testing and functional studies are planned.

32 ting and/or diarrhea; field efficacy studies are planned.

33 ed kidney transplants have occurred, and two are planned.

34 scale pivotal trials to confirm the approach are planned.

35 orrelative studies with molecular biomarkers are planned.

36 he racial disparities observed in this study are planned.

37 tive clinical validation and utility studies are planned.

38 organ damage, and long-term end point trials are planned.

39 herapy in dosing schedules similar to adults are planned.

40 the added burden associated with IP therapy are planned.

41 d studies to demonstrate protective efficacy are planned.

42 umab in combination with CART19 cell therapy are planned.

43 vaccine coadministered with measles vaccine are planned.

44 an earlier time window after stroke (<36 h) are planned.

45 patients for whom primary surgical resection was planned.

46 = .025, a target sample size of 352 patients was planned.

47 r invasive or noninvasive diagnostic testing was planned.

48 whom a switch from natalizumab to fingolimod was planned.

49 Subsequently, a stem-cell transplantation was planned.

50 erim analyses, a sample size of 900 patients was planned.

51 formal statistical comparison between groups was planned.

52 for whom an early revascularization strategy was planned.

53 No formal hypothesis testing was planned.

54 of 1.075), followed by superiority testing, was planned.

55 e sites, all in sites for which radiotherapy was planned.

56 Close follow-up was planned.

57 Meta-analysis of the primary outcome was planned.

58 ilated patients in whom fluid administration was planned.

59 tant changes to the intervention versus what was planned.

60 ulcerative colitis, and phase 3 studies have been planned.

61 0% of rehospitalizations were likely to have been planned.

62 ry and axillary lymph node dissection (ALND) were planned.

63 e not blinded, and no inferential statistics were planned.

64 Two interim analyses were planned.

65 e interim analyses with futility assessments were planned.

66 ls (200 mg/m(2) and 150 mg/m(2) twice daily) were planned.

67 Six 28-day cycles were planned.

68 A total of 6 weekly doses of oxaliplatin were planned.

69 No statistical comparisons between groups were planned.

70 136, 86%) and control (N = 128, 81%) groups were planned.

71 Three interim analyses were planned.

72 e conditions and the first human studies are being planned.

73 trials to test this possibility are already being planned.

74 ly) and bevacizumab (15 mg/kg every 3 weeks) was planned 3 to 6 weeks later for six cycles.

75 Total mesorectal excision was planned 6 weeks after CT-RT.

76 When repair was planned, 84% (21 of 25) were successful.

77 A subgroup analysis was planned a priori in patients with a high level of pr

78 A subset analysis by incision type was planned a priori.

79 A priori subgroup analysis was planned according to the location where the study wa

80 An analysis of overall survival is planned after 248 events.

81 A final analysis was planned after 196 deaths and an interim analysis aft

82 is for recurrence-free survival (RFS), which was planned after 227 recurrences.

83 Follow-up was planned after 3 and 6 months.

84 The primary analysis was planned after 305 events.

85 Primary analysis was planned after 470 SREs.

86 One hundred subjects were planned, aged 30 to 83 years, with confirmed first-

87 ire further deliberation before such studies are planned and implemented.

88 d appropriate postsurgical management should be planned and implemented by public health authorities.

89 Post-engraftment pregnancies should be planned and the teratogenic mycophenolic acid should

90 ngs indicate that human referential pointing is planned and controlled on the basis of partner-specif

91 When research is planned and interventions are designed to interrupt t

92 -A isoforms with bevacizumab and paclitaxel, is planned and will hopefully provide us with new direct

93 During report writing, respecting both what was planned and what actually happened requires good jud

94 nding internal company documents (i.e., what was planned and what was done).

95 Of these readmissions, 44 of 122 (36.1%) were planned and 78 of 122 (63.9%) were unplanned.

96 ation was event-driven, and interim analyses were planned and conducted after approximately 120 and 2

97 e developed and country-specific innovations were planned and implemented by the country teams.

98 Most LCs (76%) involved procedures that were planned and performed according to radiographs and

99 personnel sit idle even though staffing has been planned) and a concomitant reduction in percent pro

100 dy was open label, no inferential statistics were planned, and only patients with genotype 1 or 4 inf

101 dy was open-label, no inferential statistics were planned, and sample sizes were small.

102 onary syndromes for whom invasive evaluation is planned are uncertain.

103 dependence or health-related quality of life are planned as key study outcomes, then the reliability

104 ndpoint, artificial urinary sphincter should be planned as a second stage procedure after stabilizati

105 The effort is planned as a collaboration with the scientific malari

106 ent of new conditions at long-term follow-up is planned as this registry grows and will be important

107 The study was planned as a Fleming two-stage design, enabling one

108 acknowledgement is as follows: "This Review was planned as part of the activity of the European Rena

109 Follow-up visits are planned at 1 week after first-eye surgery and 4 week

110 Follow-up visits are planned at 6, 12, 18 and 24 months.

111 Filter retrieval was planned at 3 months from placement.

112 This final OS analysis was planned at 380 deaths.

113 DLC was planned at least 6 weeks after initial antibiotic tr

114 Thienopyridine was planned at randomization in 12,410 (73%).

115 Primary outcome assessments were planned at post-treatment, 12 months post-baseline,

116 acizumab 1.25 mg/0.05 mL; 3 follow-up visits were planned at week 2, 6, and 12.

117 Longer follow-up is planned because the timeline for LF in this setting s

118 cases where pancreatic resection/anastomosis is planned, because of varying ductal anatomy, risk of d

119 Grasping movements are planned before they are executed, but how is the pre

120 Voluntary movements are widely considered to be planned before they are executed.

121 vidual patient data analysis of these trials was planned, before their results were known, to assess

122 Elective delivery was planned between 37 weeks 5 days and 38 weeks 6 days

123 Conservative treatment was planned but both of them succumbed to the illness.

124 Transarterial embolization was planned but repeat cerebral angiography prior to the

125 o observe localization errors when a saccade is planned, but abruptly aborted just before its executi

126 Reintroduction is planned, but so far, no action has been taken.

127 Six cohorts were planned, but only 3 were enrolled (0.04, 0.15, 0.4

128 Most chemical experiments are planned by human scientists and therefore are subjec

129 Artery-specific SPECT/CT partition modeling was planned by experienced nuclear medicine physicians.

130 m channel blockers in these disorders should be planned carefully.

131 can be managed most effectively if pregnancy is planned, clinicians should discuss the issue of pregn

132 ng urethroplasty and further management will be planned depending upon the presence of any remaining

133 Ideally, pregnancy should be planned during remission from bipolar disorder and li

134 Until better trials are planned, executed and published, much of what we kno

135 A second cycle of chemotherapy was planned following a 1-week rest.

136 program 47 years ago, however, new missions are planned for an orbital outpost.

137 suggest that increased health costs have to be planned for over a long time horizon.

138 had been the subject of much writing and had been planned for, detection of and the appropriate respo

139 Most clinical trials being planned for individuals in the prediagnostic stage

140 Follow-up is planned for a minimum of 4 years, with annual visits.

141 with the therapeutic nuclide (188)Re, which is planned for the near future.

142 up of patients with rheumatoid arthritis, as is planned for the next phase of clinical trials.

143 Colonoscopic follow-up evaluation was planned for 1 and 3 years after randomization.

144 At randomisation, an invasive strategy was planned for 13 408 (72.0%) of 18 624 patients hospit

145 ised, double-blind, placebo-controlled trial was planned for 45 hospitals in Argentina, Australia, De

146 primary de novo renal transplant recipients was planned for 48 months but terminated early because o

147 This trial was planned for 52-76 weeks, with primary efficacy analy

148 A per-protocol analysis was planned for all children who provided a stool sample

149 uding the kidneys, within 3 h before surgery was planned for all patients.

150 A tunnel technique was planned for both areas in the mandible.

151 Treatment was planned for eight cycles.

152 Radiotherapy was planned for incomplete response or initial bulk dise

153 A priori subgroup analysis was planned for patients who received a stoma at the tim

154 Plasmapheresis was planned for up to 3 months after LDLT aiming at main

155 interim analysis of overall survival, which was planned for when approximately 67% (n=330) of 492 ex

156 therapy, whereas troponin-negative patients were planned for 1-month dual antiplatelet therapy.

157 h treatment arms, troponin-positive patients were planned for 12-month dual antiplatelet therapy, whe

158 th detectable Tg and a negative neck US, who were planned for blind (131)I therapy.

159 Patients with chronic pancreatitis who were planned for elective surgical treatment were random

160 Four hundred seventy-five eligible patients were planned for enrollment.

161 paired recipients undergoing allogeneic HSCT were planned for enrolment at 16 transplant centres in t

162 SCLC) who either (1) had a new diagnosis and were planned for initial therapy or (2) had developed ac

163 en were enrolled in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DP

164 s includes only women recruited to ICON8 who were planned for neoadjuvant chemotherapy followed by DP

165 with the DT catheter (study group); patients were planned for PV remapping after 3 months, regardless

166 d resistance to an EGFR kinase inhibitor and were planned for rebiopsy underwent initial blood sampli

167 Fifteen patients were planned for single port transanal surgery.

168 t device patients with stable renal function were planned for this prospective, randomized, open-labe

169 Interim analyses were planned for when 84 patients had been allocated tre

170 Postoperative radiation was planned if R0 resection was not achieved.

171 A test for superiority was planned if rivaroxaban proved to be noninferior to e

172 gh risk for stent thrombosis, surgery should be planned in a hospital with cardiac catheterization fa

173 Actions can be planned in either an intrinsic (body-based) reference

174 Similar trials are either underway or being planned in Europe and Asia.

175 e focus on the Morrow Pacific export project being planned in Oregon by Ambre Energy that would ship

176 Increasingly, clinical trials are being planned in patients with mild cognitive impairment

177 A dose escalation is planned in a subsequent phase I/II study to assess th

178 ns routinely given at 9 and 15 months of age is planned in Burkina Faso.

179 Further validation of kSORT is planned in prospective clinical observational and int

180 ents where buccal tooth movement (expansion) is planned in the anterior mandible or involving the max

181 of renal allografts and further discounting is planned in the new United Network of Organ Sharing ki

182 the basis of these results, a clinical trial is planned in which patients bearing a variety of tumor

183 Hepatic surgery was planned in 241 patients but abandoned in nine becaus

184 Oncological hub-and-spoke program was planned in 29 departments, but was active only in 10

185 through 1 year, and angiography at 13 months was planned in 50 MGuard patients.

186 Sedation was planned in 66 (95.7%) patients and was successful in

187 s for comparison, continuing current therapy was planned in 79% when scans showed no change or a decr

188 The present substudy, which was planned in the NeoALTTO main protocol, evaluated the

189 d with a higher rate of perinatal death than was planned in-hospital birth (3.9 vs. 1.8 deaths per 10

190 4 shoulder joint and 24 hip joint injections were planned in 12 human cadavers.

191 Two or more categories of systemic therapy were planned in 56% of prostate and 43% of breast cancer

192 Meta-analyses were planned in treatment-naive and treatment-experience

193 cklist recommends a full description of what is planned; it does not prescribe how to design or condu

194 Whenever a 2-stent technique is planned, modified T-stenting appears the most promisi

195 on of sirolimus in treatment-refractory iMCD is planned (NCT03933904).

196 Studies are planned of the expression of ABC transporters in eye

197 primary end points (median, seven per trial) were planned, of which 373 (64.4%; median, five per tria

198 Surgery was planned on day 29.

199 ngle coordinate in the past and only need to be planned one radian ahead.

200 Several trials are planned or are in progress to assess whether minocyc

201 herapies versus nonreperfused control groups are planned or in progress.

202 Although randomized clinical trials are planned or ongoing, current scientific evidence rest

203 exciting clinical trials that are currently being planned or underway.

204 nt groups; no statistical hypothesis testing was planned or conducted.

205 um; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation.

206 cer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB.

207 noma in situ (when breast-conserving surgery is planned) or are pregnant should not undergo SNB.

208 ently to enable trials of neuroprotection to be planned, powered and implemented.

209 Therefore, this cross-sectional study was planned, primarily, to determine the ability of Four

210 All outcomes were planned prior to data collection.

211 Enrollment of 230 patients was planned, providing 90% power to observe a 20% differ

212 Future steps were planned regarding 1) recognizing, preventing, and t

213 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis.

214 ts in whom subclavian central line insertion is planned should have both sides examined by ultrasound

215 uses of FLV in children so that services can be planned that promote independence, improve quality of

216 stributed health data networks are currently being planned that could cover millions of people, permi

217 nts from three sites were enrolled if an SBT was planned the following day.

218 Four dose levels were planned: the starting dose level of alpelisib 250 m

219 ersus traditional open gastrectomy (OG) have been planned, their surgical outcomes reported but their

220 n patients with trauma and severe hemorrhage is planned.This is an open-access article distributed un

221 United Kingdom and the United States, which are planned to commence shortly.

222 Further studies are planned to design and synthesize 3CTAs with enhanced

223 Further experiments are planned to determine if facial features or a protect

224 Studies of higher doses are planned to determine the optimal efficacious dose of

225 l 'next-generation' antibody; future studies are planned to determine the potential for affinity-driv

226 Further studies are planned to determine whether the addition of nelarab

227 Cost-effectiveness analyses are planned to evaluate the healthcare costs and health

228 Larger clinical trials are planned to further validate these data.

229 Future studies are planned to investigate possible therapeutic benefits

230 Dedicated transgender clinics are planned to provide comprehensive care, including PrE

231 Clinical trials are planned to test MAb 201, a fully human MAb specific

232 mber of trials have been done, initiated, or are planned to test new immune modulators for cancer the

233 Additional studies are planned to validate the ability of the technique to

234 cushion, so a 1.5-mm minimal distance should be planned to avoid potential nerve injury.

235 this prespecified final analysis, which had been planned to be performed after approximately 240 dea

236 The present study has been planned to investigate topical application of a nov

237 Follow-up is planned to 2 years, and here we present findings at e

238 The carrier protein is planned to be genetically altered pertussis toxoid.

239 data of UniProt (Universal Protein Resource) is planned to be publicly available on the UniProt web p

240 , because the pending zero-tolerance-concept is planned to be replaced by accurate thresholds.

241 Enrollment began in 2012 and is planned to continue in multiple stages through 2017.

242 inimal activity in the bladder, further work is planned to correlate imaging findings with histopatho

243 Expanded surveillance is planned to define the dynamics of transmission.

244 ander Philae onboard the Rosetta space probe is planned to detach from the orbiter and soft-land on t

245 Long-term follow-up is planned to determine whether the observed changes are

246 Future clinical study is planned to develop this drug for use in OM management

247 Further work is planned to dissect underlying mechanisms, and explore

248 geneous high-risk group, and a phase 3 study is planned to fully assess efficacy.

249 An additional study is planned to fully evaluate safety and efficacy at the

250 our patient are good and life-long follow-up is planned to prevent late complications.

251 Results: In 24 cases, radiotherapy was planned to a clinical target volume consisting of th

252 In 24 cases, radiotherapy was planned to a clinical target volume consisting of th

253 In 21 cases, radiotherapy was planned to a clinical target volume consisting of th

254 One interim analysis was planned to allow the study to stop early for efficac

255 This study was planned to assess whether vitamin D3 is a protective

256 The amount of therapist time in CCBT was planned to be about one-third that in CBT.

257 External validation was planned to be performed on the cohort of the two rec

258 oncerted Action on SIDS (ECAS) investigation was planned to bring together data from these and new st

259 als (RCTs) in this area is small and a trial was planned to compare midazolam and clonidine, two seda

260 f 1,113 evaluable patients per treatment arm was planned to confirm noninferiority with expected CR o

261 etween February 2010 and May 2012; treatment was planned to continue until patients were followed-up

262 Translational research was planned to correlate the expression of apoptotic and

263 controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the tr

264 The present study was planned to determine that relationship, using cardia

265 Finally, a set of in vitro studies was planned to dissect the biological functions exerted

266 This study about the prophylactic treatment was planned to focus on the effect in the generation of

267 The present study was planned to investigate the therapeutic actions of 1-

268 MATERIAL/METHODS: The prospective study was planned to qualify 50 children treated for long bone

269 y syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel.

270 An experimental design was planned to study three factors affecting the test: t

271 e final analysis of recurrence-free survival was planned to take place after 214 or more events of di

272 This final efficacy analysis was planned to take place after 940 DFS events.

273 randomly assigned 4752 patients in whom CABG was planned to undergo the procedure off-pump or on-pump

274 A placebo group of 14 subjects was planned to verify placebo response rate and estimate

275 Follow-up telephone calls and clinic visits were planned to alternate at 3-month intervals after ran

276 Approximately 2,522 patients were planned to be enrolled < or =12 hrs after the onset

277 No corticosteroids were planned to be given after the first week postoperat

278 Up to 174 subjects were planned to be randomized into either the DJBL or th

279 05 and beta = .10, 190 p53-positive patients were planned to be randomly assigned to detect an absolu

280 Our treatments were planned to deliver the maximally tolerated radiatio

281 the resolution of deletion mapping, screens were planned to distribute deletion breakpoints evenly a

282 Multiple sensitivity analyses were planned to examine the impact of each assumption on

283 Analyses were planned to have a minimum median follow-up of 15 mo

284 atients (n = 436) and for those patients who were planned to receive 400 mg/day monotherapy (n = 347)

285 Center from March 1989 to April 2016 and who were planned to receive EPx2 were included.

286 ation and a performance status of 0 to 2 who were planned to receive first-line palliative therapy.

287 Baseline and 6 follow-up visits were planned to record disease activity and collect bloo

288 As a revamp of research is being planned, unique issues that face the research comm

289 The approach to the cortex was planned using an MRI-based 3D model of the sheep's b

290 chen, Germany), in whom fluid administration was planned were entered in a " dynamic" study.

291 clinically N0 neck side for which dissection was planned were included.

292 (IOPs) >/= 18 mmHg in whom an aqueous shunt was planned were randomized to an AGV or a BGI.

293 whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or

294 Meta-analysis was planned where clinical study heterogeneity allowed.

295 d prediagnosis Huntington disease trials can be planned with PFS, and there is evidence of generaliza

296 ilarities between the target CA active sites was planned with benzenesulfonamide derivatives and, for

297 quential liver transplant followed by a HSCT was planned with her mother as the donor for both liver

298 ee consecutive ALDLTs (71 right and 12 left) were planned with 3D CASP.

299 eldkirchen, Germany) in whom fluid expansion was planned, with (intra-abdominal hypertension+) and wi

300 acy analysis of TC versus the TaxAC regimens was planned, with invasive disease-free survival (IDFS)